Summary

The reliable assessment of metabolic dysfunction-associated steatotic liver disease (MASLD) is crucial for determining the stage of the disease, initiating appropriate treatments and monitoring the course of therapy. To date, a liver biopsy has often been necessary for this purpose. In this invasive procedure, a tissue sample is taken and examined.

AI summaries can be wrong sometimes—always verify important details using the source article.